View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsSilo Wellness 配当と自社株買い配当金 基準チェック /06Silo Wellness配当金を支払った記録がありません。主要情報n/a配当利回り0.0001%バイバック利回り総株主利回り0.0001%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Aug 30+ 1 more updateSilo Wellness Inc. announced that it expects to receive CAD 0.25 million in fundingSilo Wellness Inc. announced a best-efforts private placement to issue 12,500,000 common shares at a price of CAD 0.02 per share for the gross proceeds of CAD 250,000 on August 29, 2023.お知らせ • Feb 18Silo Wellness Inc. Announces Resignation of Gerard Lee from as A Director of the BoardSilo Wellness Inc. accepted the resignation of Gerard Lee from his position as a director of the board, effective immediately. The board of directors includes Greg Biniowsky (independent director), Vancouver lawyer; Simon Bababeygy, M.D. (independent director), California physician; Michael Hartman, California pharmaceutical chemist; and Mike Arnold, Oregon lawyer.お知らせ • Oct 18Silo Wellness Inc. (CNSX:SILO) completed the acquisition of Dyscovry Science Ltd.Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd. on May 31, 2022. Silo Wellness Inc. (CNSX:SILO) entered into a definitive share exchange agreement to acquire Dyscovry Science Ltd. on September 27, 2022. Pursuant to the terms of the Share Exchange Agreement, Silo will acquire 100% of the issued and outstanding shares of Dyscovry in exchange for 12,762,325 (for a total of 49% of the issued shares post closing of the transaction) common shares in the capital of Silo (the "Payment Shares"). The Payment Shares issued for shares of Dyscovry shall be subject to restrictions on resale for a period of 36 months from closing of the Acquisition and shall be released on a schedule consistent with the release schedule for an "emerging issuer" prescribed by section 4.3 of National Policy 46-201- Escrow for Initial Public Offerings. Silo has also agreed to pay approximately CAD 120,000 of Dyscovry founder's debt in twelve equal monthly installments, and in any event, the total debt shall be paid no later than twelve months from the Closing Date. Subject to the completion of the due diligence process and the completion of the definitive agreement, the transaction contemplates Silo will acquire 100% of the issued and outstanding shares of Dyscovry in exchange of 49% of the issued shares. Following closing, Dyscovry shall have the right to immediately nominate one director to the board of directors of Silo. Closing of the Transaction is subject to customary closing conditions and applicable regulatory approvals, including the approval of the CSE and the shareholders of Dyscovry if required. Silo Wellness Inc. (CNSX:SILO) completed the acquisition of Dyscovry Science Ltd. on October 17, 2022. Upon closing of the transaction, CFO Winfield Ding has resigned from the board of directors and Dyscovry founder Gerard Lee of Toronto has been appointed director. Winfield Ding will continue as Chief Financial Officer.お知らせ • Jun 10Silo Wellness Inc. Announces Change of Chief Executive OfficerSilo Wellness Inc. announced that founder and chairman of the board of directors Mike Arnold is assuming the role of the company's interim chief executive officer to continue to lead the company through its planned acquisition of Dyscovry Science Ltd. and in its planned Oregon psilocybin business objectives. The company and former CEO Douglas K. Gordon have agreed to Mr. Gordon stepping down as CEO, but he will remain involved in the business, including pursuit of global distribution opportunities for sales of Marley One. During his tenure at Silo Wellness, Mr. Gordon was responsible for the creation of the Marley One global mushroom brand in collaboration with the family of legendary musician Bob Marley and for launching psychedelic retreats in Oregon and Jamaica, a first for a publicly traded company. He also led the Company through its public listing in March of 2021 and two major financings. CEO Mike Arnold founded Silo Wellness in 2018 and was CEO from inception until August 2020. He is an experienced Oregon trial attorney. As the company's president and chairman of the board of directors, he has been responsible for the Company's Ontario Securities Commission and Canadian Securities Exchange compliance, investor relations, financing, and corporate development. In the last five years he has successfully raised over $12 million for his startups. Mike received his Bachelor of Arts from Truman State University (Kirksville, Missouri) and Juris Doctor from the University of Oregon School of Law. He is an avid outdoorsman and rafting guide.お知らせ • Jun 01Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd.Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd. on May 31, 2022. Subject to the completion of the due diligence process and the completion of the definitive agreement, the transaction contemplates Silo Wellness Inc. acquiring 100% of Dyscovry's shares in exchange for 49% of the issued outstanding securities of the Company.お知らせ • Apr 15Silo Wellness Inc. announced that it expects to receive CAD 5.95 million in funding from Alpha Blue Ocean Investment GroupSilo Wellness Inc. announced that it has entered into an subscription agreement for a private placement of convertible debentures for gross proceeds of up to CAD 5,950,000 on April 14, 2022. The transaction will include participation from new investor Global Tech Opportunities 14, a fund managed by Alpha Blue Ocean Investment Group. The subscription agreement provides a commitment to fund the corporation up to CAD 5,950,000 by subscribing for CAD 7,300,000 aggregate principal amount of convertible debentures, inclusive of the commitment fee, in twenty tranches, each in the aggregate principal amount of CAD 350,000 each tranche convertible upon notice at the lower of the closing price of the common shares on the CSE at the time of delivery of the relevant conversion notice to the corporation and CAD 0.05; the convertible debentures shall be subscribed for at a subscription price of eighty-five percent of the par value of the convertible debentures. 41,650,000 warrants exercisable at CAD 0.05 shall be attached to the first tranche. In connection with the subscription agreement, the company has agreed to pay the subscriber a commitment fee of CAD 300,000 where CAD 150,000 shall be added to the principal amount of the debentures issued in connection with each of the first two tranches.お知らせ • Feb 04Silo Wellness Inc. announced that it expects to receive $0.494988 million in funding from Orthogonal Thinker, Inc., Investment ArmSilo Wellness Inc. announced that it has entered into an subscription agreement to issue 12,555,180 units at a price of $0.039425 per unit for gross proceeds of up to $494,988 on February 3, 2022. The transaction will include participation from new investor Orthogonal Thinker, Inc., Investment Arm. Each unit will consist of one common share and one common share purchase warrant. Each warrant will be exercisable at CAD 0.05 per share for two years following the closing date of the offering. The offering is subject to customary closing conditions, applicable regulatory approvals, including receipt of certain voting support agreements from certain shareholders of the company. David Nikzad and Jason Hobson from Orthogonal Thinker, Inc., Investment Arm will join company's board of director.お知らせ • Jun 25Silo Wellness Inc. Debuts Marley One, the First Global Functional and Psychedelic Mushroom Brand, in Collaboration with the Bob Marley FamilySilo Wellness Inc. announced the launch of Marley One, the first global functional and psychedelic mushroom consumer brand, in collaboration with the family of Bob Marley. The initial product offering will include a range of functional mushroom tinctures with unique blends highlighting the brand’s connection to Jamaica, including species such as cordyceps, lion's mane, chaga, reishi and turkey tail that offer a range of unique health and wellness benefits, from immunity and gut health to cognitive function and sleep enhancement. The Company intends to launch a psychedelic mushroom product line under the Marley name later this year, to be followed by additional functional mushroom products including gummies, capsules and cosmetics. In March, Silo Wellness announced a multi-year licensing agreement with the family of global reggae icon Bob Marley for the exclusive worldwide rights to brand, market and sell a distinct product line of functional and psychedelic mushrooms. At launch, the Marley One product line includes: One Mind: A coffee-flavored blend of lion’s mane and L-theanine designed to improve focus and cognitive function. One Flow: A peppermint-flavored blend of cordyceps and ginseng designed to enhance physical endurance and mental function. One Harmony: A mango-flavored blend of chaga and ginger designed to stimulate gut health and improve digestion. One Body: A berry-flavored blend of turkey tail and astragalus designed to support immune health. One Rest: A vanilla-flavored blend of reishi and GABA designed to help reduce tension and stress and improve quality of sleep.決済の安定と成長配当データの取得安定した配当: SILF.Fの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: SILF.Fの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Silo Wellness 配当利回り対市場SILF.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (SILF.F)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Pharmaceuticals)2.1%アナリスト予想 (SILF.F) (最長3年)n/a注目すべき配当: SILF.Fは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: SILF.Fは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: SILF.Fの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: SILF.Fが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/11/25 21:36終値2023/08/28 00:00収益2023/07/31年間収益2022/10/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Silo Wellness Inc. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Aug 30+ 1 more updateSilo Wellness Inc. announced that it expects to receive CAD 0.25 million in fundingSilo Wellness Inc. announced a best-efforts private placement to issue 12,500,000 common shares at a price of CAD 0.02 per share for the gross proceeds of CAD 250,000 on August 29, 2023.
お知らせ • Feb 18Silo Wellness Inc. Announces Resignation of Gerard Lee from as A Director of the BoardSilo Wellness Inc. accepted the resignation of Gerard Lee from his position as a director of the board, effective immediately. The board of directors includes Greg Biniowsky (independent director), Vancouver lawyer; Simon Bababeygy, M.D. (independent director), California physician; Michael Hartman, California pharmaceutical chemist; and Mike Arnold, Oregon lawyer.
お知らせ • Oct 18Silo Wellness Inc. (CNSX:SILO) completed the acquisition of Dyscovry Science Ltd.Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd. on May 31, 2022. Silo Wellness Inc. (CNSX:SILO) entered into a definitive share exchange agreement to acquire Dyscovry Science Ltd. on September 27, 2022. Pursuant to the terms of the Share Exchange Agreement, Silo will acquire 100% of the issued and outstanding shares of Dyscovry in exchange for 12,762,325 (for a total of 49% of the issued shares post closing of the transaction) common shares in the capital of Silo (the "Payment Shares"). The Payment Shares issued for shares of Dyscovry shall be subject to restrictions on resale for a period of 36 months from closing of the Acquisition and shall be released on a schedule consistent with the release schedule for an "emerging issuer" prescribed by section 4.3 of National Policy 46-201- Escrow for Initial Public Offerings. Silo has also agreed to pay approximately CAD 120,000 of Dyscovry founder's debt in twelve equal monthly installments, and in any event, the total debt shall be paid no later than twelve months from the Closing Date. Subject to the completion of the due diligence process and the completion of the definitive agreement, the transaction contemplates Silo will acquire 100% of the issued and outstanding shares of Dyscovry in exchange of 49% of the issued shares. Following closing, Dyscovry shall have the right to immediately nominate one director to the board of directors of Silo. Closing of the Transaction is subject to customary closing conditions and applicable regulatory approvals, including the approval of the CSE and the shareholders of Dyscovry if required. Silo Wellness Inc. (CNSX:SILO) completed the acquisition of Dyscovry Science Ltd. on October 17, 2022. Upon closing of the transaction, CFO Winfield Ding has resigned from the board of directors and Dyscovry founder Gerard Lee of Toronto has been appointed director. Winfield Ding will continue as Chief Financial Officer.
お知らせ • Jun 10Silo Wellness Inc. Announces Change of Chief Executive OfficerSilo Wellness Inc. announced that founder and chairman of the board of directors Mike Arnold is assuming the role of the company's interim chief executive officer to continue to lead the company through its planned acquisition of Dyscovry Science Ltd. and in its planned Oregon psilocybin business objectives. The company and former CEO Douglas K. Gordon have agreed to Mr. Gordon stepping down as CEO, but he will remain involved in the business, including pursuit of global distribution opportunities for sales of Marley One. During his tenure at Silo Wellness, Mr. Gordon was responsible for the creation of the Marley One global mushroom brand in collaboration with the family of legendary musician Bob Marley and for launching psychedelic retreats in Oregon and Jamaica, a first for a publicly traded company. He also led the Company through its public listing in March of 2021 and two major financings. CEO Mike Arnold founded Silo Wellness in 2018 and was CEO from inception until August 2020. He is an experienced Oregon trial attorney. As the company's president and chairman of the board of directors, he has been responsible for the Company's Ontario Securities Commission and Canadian Securities Exchange compliance, investor relations, financing, and corporate development. In the last five years he has successfully raised over $12 million for his startups. Mike received his Bachelor of Arts from Truman State University (Kirksville, Missouri) and Juris Doctor from the University of Oregon School of Law. He is an avid outdoorsman and rafting guide.
お知らせ • Jun 01Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd.Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd. on May 31, 2022. Subject to the completion of the due diligence process and the completion of the definitive agreement, the transaction contemplates Silo Wellness Inc. acquiring 100% of Dyscovry's shares in exchange for 49% of the issued outstanding securities of the Company.
お知らせ • Apr 15Silo Wellness Inc. announced that it expects to receive CAD 5.95 million in funding from Alpha Blue Ocean Investment GroupSilo Wellness Inc. announced that it has entered into an subscription agreement for a private placement of convertible debentures for gross proceeds of up to CAD 5,950,000 on April 14, 2022. The transaction will include participation from new investor Global Tech Opportunities 14, a fund managed by Alpha Blue Ocean Investment Group. The subscription agreement provides a commitment to fund the corporation up to CAD 5,950,000 by subscribing for CAD 7,300,000 aggregate principal amount of convertible debentures, inclusive of the commitment fee, in twenty tranches, each in the aggregate principal amount of CAD 350,000 each tranche convertible upon notice at the lower of the closing price of the common shares on the CSE at the time of delivery of the relevant conversion notice to the corporation and CAD 0.05; the convertible debentures shall be subscribed for at a subscription price of eighty-five percent of the par value of the convertible debentures. 41,650,000 warrants exercisable at CAD 0.05 shall be attached to the first tranche. In connection with the subscription agreement, the company has agreed to pay the subscriber a commitment fee of CAD 300,000 where CAD 150,000 shall be added to the principal amount of the debentures issued in connection with each of the first two tranches.
お知らせ • Feb 04Silo Wellness Inc. announced that it expects to receive $0.494988 million in funding from Orthogonal Thinker, Inc., Investment ArmSilo Wellness Inc. announced that it has entered into an subscription agreement to issue 12,555,180 units at a price of $0.039425 per unit for gross proceeds of up to $494,988 on February 3, 2022. The transaction will include participation from new investor Orthogonal Thinker, Inc., Investment Arm. Each unit will consist of one common share and one common share purchase warrant. Each warrant will be exercisable at CAD 0.05 per share for two years following the closing date of the offering. The offering is subject to customary closing conditions, applicable regulatory approvals, including receipt of certain voting support agreements from certain shareholders of the company. David Nikzad and Jason Hobson from Orthogonal Thinker, Inc., Investment Arm will join company's board of director.
お知らせ • Jun 25Silo Wellness Inc. Debuts Marley One, the First Global Functional and Psychedelic Mushroom Brand, in Collaboration with the Bob Marley FamilySilo Wellness Inc. announced the launch of Marley One, the first global functional and psychedelic mushroom consumer brand, in collaboration with the family of Bob Marley. The initial product offering will include a range of functional mushroom tinctures with unique blends highlighting the brand’s connection to Jamaica, including species such as cordyceps, lion's mane, chaga, reishi and turkey tail that offer a range of unique health and wellness benefits, from immunity and gut health to cognitive function and sleep enhancement. The Company intends to launch a psychedelic mushroom product line under the Marley name later this year, to be followed by additional functional mushroom products including gummies, capsules and cosmetics. In March, Silo Wellness announced a multi-year licensing agreement with the family of global reggae icon Bob Marley for the exclusive worldwide rights to brand, market and sell a distinct product line of functional and psychedelic mushrooms. At launch, the Marley One product line includes: One Mind: A coffee-flavored blend of lion’s mane and L-theanine designed to improve focus and cognitive function. One Flow: A peppermint-flavored blend of cordyceps and ginseng designed to enhance physical endurance and mental function. One Harmony: A mango-flavored blend of chaga and ginger designed to stimulate gut health and improve digestion. One Body: A berry-flavored blend of turkey tail and astragalus designed to support immune health. One Rest: A vanilla-flavored blend of reishi and GABA designed to help reduce tension and stress and improve quality of sleep.